Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?-Letter
- PMID: 34607877
- PMCID: PMC8500478
- DOI: 10.1158/1940-6207.CAPR-21-0233
Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?-Letter
Comment in
-
Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?-Response.Cancer Prev Res (Phila). 2021 Oct;14(10):975-976. doi: 10.1158/1940-6207.CAPR-21-0257. Cancer Prev Res (Phila). 2021. PMID: 34607878 Free PMC article. No abstract available.
Comment on
-
Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?Cancer Prev Res (Phila). 2021 Mar;14(3):373-382. doi: 10.1158/1940-6207.CAPR-20-0426. Epub 2020 Nov 3. Cancer Prev Res (Phila). 2021. PMID: 33148677 Free PMC article.
References
-
- Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020;69(1):7–17. doi: 10.1136/gutjnl-2019-319352. Epub 2019 Oct 31. - DOI - PMC - PubMed
-
- Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthai E, Carrato A, et al. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. J Clin Oncol 2016;34(17):2010–9 doi 10.1200/JCO.2015.64.0730. - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical